{"doc_id": "33113295", "type of study": "Therapy", "title": "", "abstract": "SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.\nSevere acute respiratory syndrome coronavirus 2\u00a0(SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening.\nVirus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization.\nIn this ongoing phase 2 trial involving outpatients with recently diagnosed mild or moderate Covid-19, we randomly assigned 452 patients to receive a single intravenous infusion of neutralizing antibody LY-CoV555 in one of three doses (700 mg, 2800 mg, or 7000 mg) or placebo and evaluated the quantitative virologic end points and clinical outcomes.\nThe primary outcome was the change from baseline in the viral load at day 11.\nThe results of a preplanned interim analysis as of September 5, 2020, are reported here.\nAt the time of the interim analysis, the observed mean decrease from baseline in the log viral load for the entire population was -3.81, for an elimination of more than 99.97% of viral RNA.\nFor patients who received the 2800-mg dose of LY-CoV555, the difference from placebo in the decrease from baseline was -0.53 (95% confidence interval [CI], -0.98 to -0.08; P\u2009=\u20090.02), for a viral load that was lower by a factor of 3.4.\nSmaller differences from placebo in the change from baseline were observed among the patients who received the 700-mg dose (-0.20; 95% CI, -0.66 to 0.25; P\u2009=\u20090.38) or the 7000-mg dose (0.09; 95% CI, -0.37 to 0.55; P\u2009=\u20090.70).\nOn days 2 to 6, the patients who received LY-CoV555 had a slightly lower severity of symptoms than those who received placebo.\nThe percentage of patients who had a Covid-19-related hospitalization or visit to an emergency department was 1.6% in the LY-CoV555 group and 6.3% in the placebo group.\nIn this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.).\nCopyright \u00a9 2020 Massachusetts Medical Society.\n", "Evidence Map": {"Enrollment": [{"term": "Outpatients", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 57}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 71}, {"term": "outpatients", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 51}, {"term": "recently diagnosed mild or moderate Covid-19", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 101}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 .", "Evidence Elements": {"Participant": [{"term": "Outpatients", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 57}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 71}], "Intervention": [{"term": "SARS-CoV-2 Neutralizing Antibody LY-CoV555", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 42, "has_chemical": [{"text": "antibody", "maps_to": "C0003241:antibody", "start": 24, "end": 32}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) causes coronavirus disease 2019 ( Covid-19 ) , which is most frequently mild yet can be severe and life-threatening .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Virus-neutralizing monoclonal antibodies are predicted to reduce viral load , ameliorate symptoms , and prevent hospitalization .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [{"term": "reduce", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 64}], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "In this ongoing phase 2 trial involving outpatients with recently diagnosed mild or moderate Covid-19 , we randomly assigned 452 patients to receive a single intravenous infusion of neutralizing antibody LY-CoV555 in one of three doses ( 700 mg , 2800 mg , or 7000 mg ) or placebo and evaluated the quantitative virologic end points and clinical outcomes .", "Evidence Elements": {"Participant": [{"term": "outpatients", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 51}, {"term": "recently diagnosed mild or moderate Covid-19", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 101}], "Intervention": [{"term": "neutralizing antibody LY-CoV555", "negation": "affirmed", "UMLS": {}, "start": 182, "end": 213, "has_chemical": [{"text": "antibody", "maps_to": "C0003241:antibody", "start": 13, "end": 21}], "has_relation": "N/A"}, {"term": "doses", "negation": "affirmed", "UMLS": {}, "start": 230, "end": 235, "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 273, "end": 280, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "quantitative virologic", "negation": "affirmed", "UMLS": {}, "start": 299, "end": 321}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was the change from baseline in the viral load at day 11 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "change from baseline in the viral load", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 66}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The results of a preplanned interim analysis as of September 5 , 2020 , are reported here .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "At the time of the interim analysis , the observed mean decrease from baseline in the log viral load for the entire population was -3.81 , for an elimination of more than 99.97 % of viral RNA .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "observed", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 50}, {"term": "mean decrease from baseline in the log viral load", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 100}, {"term": "elimination of more than 99.97 %", "negation": "affirmed", "UMLS": {}, "start": 146, "end": 178}], "Observation": [{"term": "-3.81", "negation": "affirmed", "UMLS": {}, "start": 131, "end": 136}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "For patients who received the 2800-mg dose of LY-CoV555 , the difference from placebo in the decrease from baseline was -0.53 ( 95 % confidence interval [ CI ] , -0.98 to -0.08 ; P = 0.02 ) , for a viral load that was lower by a factor of 3.4 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "2800-mg dose of LY-CoV555", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 55, "has_relation": "N/A"}, {"term": "placebo in the decrease from baseline", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 115, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "difference", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 72}, {"term": "viral", "negation": "affirmed", "UMLS": {}, "start": 198, "end": 203}], "Observation": [{"term": "-0.53", "negation": "affirmed", "UMLS": {}, "start": 120, "end": 125}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "2800-mg dose of LY-CoV555", "has_relation": "N/A"}, "Observation": "-0.53", "Outcome": "difference", "Count": ""}, {"Intervention": {"term": "2800-mg dose of LY-CoV555", "has_relation": "N/A"}, "Observation": "-0.53", "Outcome": "viral", "Count": ""}, {"Intervention": {"term": "placebo in the decrease from baseline", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "-0.53", "Outcome": "difference", "Count": ""}, {"Intervention": {"term": "placebo in the decrease from baseline", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "-0.53", "Outcome": "viral", "Count": ""}]}, {"Section": "RESULTS", "Text": "Smaller differences from placebo in the change from baseline were observed among the patients who received the 700-mg dose ( -0.20 ; 95 % CI , -0.66 to 0.25 ; P = 0.38 ) or the 7000-mg dose ( 0.09 ; 95 % CI , -0.37 to 0.55 ; P = 0.70 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 32, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "700-mg dose", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 122, "has_relation": "N/A"}, {"term": "7000-mg dose", "negation": "affirmed", "UMLS": {}, "start": 177, "end": 189, "has_relation": "N/A"}], "Outcome": [{"term": "change from baseline", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 60}], "Observation": [{"term": "Smaller differences", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 19}, {"term": "0.09", "negation": "affirmed", "UMLS": {}, "start": 192, "end": 196}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "700-mg dose", "has_relation": "N/A"}, {"term": "7000-mg dose", "has_relation": "N/A"}], "Observation": "Smaller differences", "Outcome": "change from baseline", "Count": ""}, {"Intervention": {"term": "7000-mg dose", "has_relation": "N/A"}, "Observation": "0.09", "Outcome": "change from baseline", "Count": ""}]}, {"Section": "RESULTS", "Text": "On days 2 to 6 , the patients who received LY-CoV555 had a slightly lower severity of symptoms than those who received placebo .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "LY-CoV555", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 52, "has_relation": "N/A"}], "Outcome": [{"term": "severity of symptoms", "negation": "affirmed", "UMLS": {}, "start": 74, "end": 94}], "Observation": [{"term": "slightly lower", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 73}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The percentage of patients who had a Covid-19-related hospitalization or visit to an emergency department was 1.6 % in the LY-CoV555 group and 6.3 % in the placebo group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "LY-CoV555", "negation": "affirmed", "UMLS": {}, "start": 123, "end": 132, "has_relation": "N/A"}], "Outcome": [{"term": "percentage of patients who had a Covid-19-related hospitalization or visit to an emergency department", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 105}], "Observation": [{"term": "1.6 %", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 115}, {"term": "6.3 %", "negation": "affirmed", "UMLS": {}, "start": 143, "end": 148}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "LY-CoV555", "has_relation": "N/A"}, "Observation": "1.6 %", "Outcome": "percentage of patients who had a Covid-19-related hospitalization or visit to an emergency department", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "In this interim analysis of a phase 2 trial , one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time , whereas the other doses had not by day 11 . ( Funded by Eli Lilly ; BLAZE-1 ClinicalTrials.gov number , NCT04427501 . ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "one of three doses of neutralizing antibody LY-CoV555", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 99, "has_chemical": [{"text": "antibody", "maps_to": "C0003241:antibody", "start": 35, "end": 43, "has_dosage": ["three doses"]}], "has_relation": "N/A"}, {"term": "other doses", "negation": "affirmed", "UMLS": {}, "start": 181, "end": 192, "has_relation": "N/A"}], "Outcome": [{"term": "natural decline in viral load", "negation": "affirmed", "UMLS": {}, "start": 127, "end": 156}], "Observation": [{"term": "accelerate", "negation": "affirmed", "UMLS": {}, "start": 112, "end": 122}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "one of three doses of neutralizing antibody LY-CoV555", "has_chemical": [{"text": "antibody", "maps_to": "C0003241:antibody", "start": 35, "end": 43, "has_dosage": ["three doses"]}], "has_relation": "N/A"}, "Observation": "accelerate", "Outcome": "natural decline in viral load", "Count": ""}, {"Intervention": {"term": "other doses", "has_relation": "N/A"}, "Observation": "accelerate", "Outcome": "natural decline in viral load", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Massachusetts Medical Society .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}